MODERN DIAGNOSTIC AND TREATMENT ALGORITHMS FOR CHRONIC HEART FAILURE

Authors

  • Akida Jabbarova Tashkent State Medical University Author
  • Aziza Ikramova Tashkent State Medical University Author
  • Barno Ubaydullaeva Tashkent State Medical University Author

Keywords:

Chronic Heart Failure, Diagnosis, Guideline-Directed Therapy, Biomarkers, SGLT2 Inhibitors, ARNIs, Cardiology, Heart Failure Epidemiology.

Abstract

Chronic heart failure (CHF) is a complex and progressive clinical syndrome characterized by the heart's inability to meet the metabolic demands of the body. Despite advances in pharmacologic and device-based therapies, CHF continues to be associated with high morbidity and mortality rates worldwide. This paper presents a comprehensive review of current diagnostic approaches and evolving treatment strategies for CHF, with a focus on guideline-directed medical therapy (GDMT), novel pharmacological agents, non-pharmacological interventions, and the importance of multidisciplinary care models. Emerging technologies in diagnostics such as cardiac imaging, biomarkers, and digital monitoring tools are also discussed. The goal is to provide a structured framework for clinicians aiming to improve patient outcomes through evidence-based management protocols. The paper includes statistical analysis and visual representation of patient data over the years to underline the growing burden of CHF.

References

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016;37(27):2129-2200.

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-3726.

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 Guidelines for the Management of Heart Failure. Journal of the American College of Cardiology. 2017;70(6):776-803.

Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. NEJM. 2011;364(1):11-21.

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2022;79(17):e263-e421.

Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. NEJM. 2020;383(15):1413–1424.

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. NEJM. 2019;381(21):1995–2008.

Published

2025-06-24

How to Cite

MODERN DIAGNOSTIC AND TREATMENT ALGORITHMS FOR CHRONIC HEART FAILURE. (2025). Eurasian Journal of Medical and Natural Sciences, 5(6 Part 2), 65-68. https://in-academy.uz/index.php/EJMNS/article/view/11080